Oricell Therapeutics closed a pre-IPO funding round raising more than $110 million, aiming to expand its global footprint and advance a GPC3-targeted autologous CAR-T for liver cancer toward registrational trials. The company’s lead asset, Ori-C101, has completed investigator-initiated work and a registrational Phase 1 study in hepatocellular carcinoma. Oricell framed the financing as a runway extension ahead of pivotal development, with investors including Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, and Qiming Venture Partners, alongside a leading global healthcare fund. The company said it is positioning Ori-C101 to pursue global regulatory submissions and is also advancing next-generation modalities. The company’s broader pipeline includes additional programs in solid tumors and blood cancers, with plans that incorporate “armored” CAR-T approaches and in vivo CAR-T concepts. For the sector, the deal underlines how solid-tumor cell therapy remains a capital-attracting area despite manufacturing and efficacy headwinds. For biotech operators, the transaction provides a clear example of how pre-IPO structures are being used to bridge expensive CAR-T development into later-stage clinical milestones.